STOCK TITAN

[Form 4] Erasca, Inc. Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
4
Rhea-AI Filing Summary

Erasca, Inc. (ERAS) – Form 4 insider filing: Director Michael David Varney received a grant of 120,000 non-qualified stock options on 06/24/2025 at an exercise price of $1.45 per share. The options are subject to a one-year cliff; 100% vest on 06/24/2026, contingent on his continued service, and expire on 06/23/2035. No shares were purchased or sold; the transaction code “A” denotes an award. Following the grant, Varney beneficially owns 120,000 derivative securities, held directly. The filing does not list any other equity transactions or changes in common-stock ownership.

The option award aligns the director’s incentives with shareholder value creation, but also adds up to 120,000 potential new shares to the company’s fully diluted count once exercised.

Erasca, Inc. (ERAS) – Comunicazione interna Form 4: Il direttore Michael David Varney ha ricevuto una concessione di 120.000 stock option non qualificate il 24/06/2025 con un prezzo di esercizio di 1,45 $ per azione. Le opzioni prevedono un periodo di maturazione di un anno; 100% maturano il 24/06/2026, a condizione che continui il suo servizio, e scadono il 23/06/2035. Non sono state acquistate né vendute azioni; il codice transazione “A” indica un premio. Dopo la concessione, Varney detiene direttamente 120.000 strumenti derivati. La comunicazione non riporta altre operazioni azionarie o variazioni nella proprietà delle azioni ordinarie.

La concessione delle opzioni allinea gli incentivi del direttore con la creazione di valore per gli azionisti, ma comporta anche fino a 120.000 nuove azioni potenziali da aggiungere al conteggio diluito della società una volta esercitate.

Erasca, Inc. (ERAS) – Presentación interna Formulario 4: El director Michael David Varney recibió una concesión de 120,000 opciones sobre acciones no calificadas el 24/06/2025 con un precio de ejercicio de $1.45 por acción. Las opciones están sujetas a un período de adquisición de un año; 100% se consolidan el 24/06/2026, condicionado a que continúe su servicio, y expiran el 23/06/2035. No se compraron ni vendieron acciones; el código de transacción “A” indica una asignación. Tras la concesión, Varney posee directamente 120,000 valores derivados. La presentación no incluye otras transacciones de capital ni cambios en la propiedad de acciones comunes.

La concesión de opciones alinea los incentivos del director con la creación de valor para los accionistas, pero también añade hasta 120,000 acciones potenciales nuevas al conteo totalmente diluido de la compañía una vez ejercidas.

Erasca, Inc. (ERAS) – 내부자 신고서 Form 4: 이사 Michael David Varney는 2025년 6월 24일에 120,000개의 비자격 주식매수선택권을 주당 $1.45의 행사 가격으로 부여받았습니다. 이 옵션은 1년의 베스팅 기간이 있으며; 100%는 2026년 6월 24일에 베스팅되며, 계속 근무하는 것을 조건으로 하고, 2035년 6월 23일에 만료됩니다. 주식은 매수 또는 매도되지 않았으며, 거래 코드 “A”는 보상을 의미합니다. 부여 후 Varney는 직접 120,000개의 파생증권을 보유하고 있습니다. 신고서에는 다른 주식 거래나 보통주 소유권 변경 사항이 기재되어 있지 않습니다.

이 옵션 부여는 이사의 인센티브를 주주 가치 창출과 일치시키지만, 행사 시 회사의 완전 희석 주식 수에 최대 120,000주의 잠재적 신주가 추가됩니다.

Erasca, Inc. (ERAS) – Déclaration d’initié Formulaire 4 : Le directeur Michael David Varney a reçu une attribution de 120 000 options d’achat d’actions non qualifiées le 24/06/2025, avec un prix d’exercice de 1,45 $ par action. Les options sont soumises à une période d’acquisition d’un an ; 100 % acquises le 24/06/2026, sous réserve de la poursuite de son service, et expirent le 23/06/2035. Aucune action n’a été achetée ou vendue ; le code de transaction « A » indique une attribution. Après cette attribution, Varney détient directement 120 000 titres dérivés. La déclaration ne mentionne aucune autre transaction sur actions ou changement de propriété des actions ordinaires.

L’attribution des options aligne les incitations du directeur avec la création de valeur pour les actionnaires, mais ajoute également jusqu’à 120 000 actions potentielles nouvelles au nombre total d’actions diluées de la société une fois exercées.

Erasca, Inc. (ERAS) – Insider-Meldung Form 4: Direktor Michael David Varney erhielt am 24.06.2025 eine Zuteilung von 120.000 nicht qualifizierten Aktienoptionen zu einem Ausübungspreis von 1,45 $ pro Aktie. Die Optionen unterliegen einer einjährigen Sperrfrist; 100% werden am 24.06.2026 fällig, vorausgesetzt, er bleibt im Dienst, und sie verfallen am 23.06.2035. Es wurden keine Aktien gekauft oder verkauft; der Transaktionscode „A“ steht für eine Zuteilung. Nach der Zuteilung besitzt Varney direkt 120.000 derivative Wertpapiere. Die Meldung enthält keine weiteren Aktien-Transaktionen oder Änderungen im Besitz von Stammaktien.

Die Optionszuteilung richtet die Anreize des Direktors auf die Wertschöpfung für die Aktionäre aus, führt jedoch auch zu bis zu 120.000 potenziellen neuen Aktien in der vollständig verwässerten Aktienzahl des Unternehmens nach Ausübung.

Positive
  • Director incentive alignment: 120,000 options vest only after one year, encouraging continued service and long-term value focus.
Negative
  • Potential dilution: If exercised, the options would add 120,000 shares to the outstanding count.

Insights

TL;DR: Routine option grant; aligns incentives, minimal immediate impact.

The Form 4 reflects a standard equity-compensation grant to a non-employee director—120,000 options, $1.45 strike, one-year cliff. Such awards are customary in biotech governance to attract talent while conserving cash. Because the options are currently unvested and out-of-the-money until the share price exceeds $1.45, there is no near-term cash cost or EPS hit. Potential dilution of 120,000 shares (≈0.1% of a 120 million-share base, if that were the case) is modest. No red flags regarding accelerated vesting, repricing, or related-party concerns appear in the filing.

Erasca, Inc. (ERAS) – Comunicazione interna Form 4: Il direttore Michael David Varney ha ricevuto una concessione di 120.000 stock option non qualificate il 24/06/2025 con un prezzo di esercizio di 1,45 $ per azione. Le opzioni prevedono un periodo di maturazione di un anno; 100% maturano il 24/06/2026, a condizione che continui il suo servizio, e scadono il 23/06/2035. Non sono state acquistate né vendute azioni; il codice transazione “A” indica un premio. Dopo la concessione, Varney detiene direttamente 120.000 strumenti derivati. La comunicazione non riporta altre operazioni azionarie o variazioni nella proprietà delle azioni ordinarie.

La concessione delle opzioni allinea gli incentivi del direttore con la creazione di valore per gli azionisti, ma comporta anche fino a 120.000 nuove azioni potenziali da aggiungere al conteggio diluito della società una volta esercitate.

Erasca, Inc. (ERAS) – Presentación interna Formulario 4: El director Michael David Varney recibió una concesión de 120,000 opciones sobre acciones no calificadas el 24/06/2025 con un precio de ejercicio de $1.45 por acción. Las opciones están sujetas a un período de adquisición de un año; 100% se consolidan el 24/06/2026, condicionado a que continúe su servicio, y expiran el 23/06/2035. No se compraron ni vendieron acciones; el código de transacción “A” indica una asignación. Tras la concesión, Varney posee directamente 120,000 valores derivados. La presentación no incluye otras transacciones de capital ni cambios en la propiedad de acciones comunes.

La concesión de opciones alinea los incentivos del director con la creación de valor para los accionistas, pero también añade hasta 120,000 acciones potenciales nuevas al conteo totalmente diluido de la compañía una vez ejercidas.

Erasca, Inc. (ERAS) – 내부자 신고서 Form 4: 이사 Michael David Varney는 2025년 6월 24일에 120,000개의 비자격 주식매수선택권을 주당 $1.45의 행사 가격으로 부여받았습니다. 이 옵션은 1년의 베스팅 기간이 있으며; 100%는 2026년 6월 24일에 베스팅되며, 계속 근무하는 것을 조건으로 하고, 2035년 6월 23일에 만료됩니다. 주식은 매수 또는 매도되지 않았으며, 거래 코드 “A”는 보상을 의미합니다. 부여 후 Varney는 직접 120,000개의 파생증권을 보유하고 있습니다. 신고서에는 다른 주식 거래나 보통주 소유권 변경 사항이 기재되어 있지 않습니다.

이 옵션 부여는 이사의 인센티브를 주주 가치 창출과 일치시키지만, 행사 시 회사의 완전 희석 주식 수에 최대 120,000주의 잠재적 신주가 추가됩니다.

Erasca, Inc. (ERAS) – Déclaration d’initié Formulaire 4 : Le directeur Michael David Varney a reçu une attribution de 120 000 options d’achat d’actions non qualifiées le 24/06/2025, avec un prix d’exercice de 1,45 $ par action. Les options sont soumises à une période d’acquisition d’un an ; 100 % acquises le 24/06/2026, sous réserve de la poursuite de son service, et expirent le 23/06/2035. Aucune action n’a été achetée ou vendue ; le code de transaction « A » indique une attribution. Après cette attribution, Varney détient directement 120 000 titres dérivés. La déclaration ne mentionne aucune autre transaction sur actions ou changement de propriété des actions ordinaires.

L’attribution des options aligne les incitations du directeur avec la création de valeur pour les actionnaires, mais ajoute également jusqu’à 120 000 actions potentielles nouvelles au nombre total d’actions diluées de la société une fois exercées.

Erasca, Inc. (ERAS) – Insider-Meldung Form 4: Direktor Michael David Varney erhielt am 24.06.2025 eine Zuteilung von 120.000 nicht qualifizierten Aktienoptionen zu einem Ausübungspreis von 1,45 $ pro Aktie. Die Optionen unterliegen einer einjährigen Sperrfrist; 100% werden am 24.06.2026 fällig, vorausgesetzt, er bleibt im Dienst, und sie verfallen am 23.06.2035. Es wurden keine Aktien gekauft oder verkauft; der Transaktionscode „A“ steht für eine Zuteilung. Nach der Zuteilung besitzt Varney direkt 120.000 derivative Wertpapiere. Die Meldung enthält keine weiteren Aktien-Transaktionen oder Änderungen im Besitz von Stammaktien.

Die Optionszuteilung richtet die Anreize des Direktors auf die Wertschöpfung für die Aktionäre aus, führt jedoch auch zu bis zu 120.000 potenziellen neuen Aktien in der vollständig verwässerten Aktienzahl des Unternehmens nach Ausübung.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Varney Michael David

(Last) (First) (Middle)
C/O ERASCA, INC.
3115 MERRYFIELD ROW, SUITE 300

(Street)
SAN DIEGO CA 92121

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Erasca, Inc. [ ERAS ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
06/24/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock option (right to buy) $1.45 06/24/2025 A 120,000 06/24/2026(1) 06/23/2035 Common Stock 120,000 $0 120,000 D
Explanation of Responses:
1. 100% of the options to purchase shares vest on June 24, 2026, subject to the Reporting Person's continuous service to the Issuer on such vesting date.
/s/ Ebun S. Garner, as Attorney-in-Fact 06/26/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did ERAS disclose in the June 2025 Form 4?

Grant of 120,000 stock options to Director Michael David Varney at a $1.45 exercise price.

When do the ERAS options granted to Michael Varney vest?

They vest 100% on 06/24/2026, subject to continued service.

What is the exercise price and expiration of the new ERAS options?

Exercise price is $1.45; expiration date is 06/23/2035.

Did the director buy or sell ERAS common stock?

No. The filing shows only an award (code A) of options; no common-stock transactions occurred.

How many derivative securities does the director now hold?

After the grant, 120,000 options are beneficially owned directly.
Erasca, Inc.

NASDAQ:ERAS

ERAS Rankings

ERAS Latest News

ERAS Latest SEC Filings

ERAS Stock Data

393.77M
225.67M
12.4%
86.67%
11.98%
Biotechnology
Pharmaceutical Preparations
Link
United States
SAN DIEGO